Post-PCI MACE Risk in Women, Minorities, and White Men
Compared with white men, women and minorities had a higher adjusted risk of death/MI.
HealthDay News — Women and minorities undergoing percutaneous coronary intervention (PCI) with everolimus-eluting stents have a risk of major adverse cardiac events (MACE) that is similar to that of white men, according to a study published in JAMA Cardiology.
Wayne Batchelor, MD, from the Florida State University College of Medicine in Tallahassee, and colleagues examined one-year outcomes in women and minorities vs white men after PCI with everolimus-eluting stents. The pooled study included 1635 white men, 1863 women, and 1059 minority patients.
The researchers found that compared with white men, women and minorities had a higher prevalence of diabetes, prior stroke, hypertension, renal disease, and congestive heart failure but lower rates of multivessel disease, prior coronary artery bypass graft surgery, prior myocardial infarction (MI), and smoking.
Similar unadjusted 1-year MACE rates were seen between the groups (white men, 7.6%; women, 8.6%; and minorities, 9.6%); there were no significant differences after risk adjustment. Compared with white men, women and minorities had a higher adjusted risk of death/MI (odds ratios, 1.6 and 1.9, respectively); the adjusted risk of MI was increased among minorities (odds ratio, 2.6). The main driver of these differences was nonstent-related MIs.
"After contemporary everolimus-eluting stent implantation, women and minorities experience a similar risk of one-year MACE but a higher adjusted risk of recurrent ischemic events primarily because of nonstent-related MIs," the authors write.
Several authors disclosed financial ties to the pharmaceutical and medical device industries.
Batchelor W, Kandzari DE, Davis S, et al. Outcomes in women and minorities compared with white men 1 year after everolimu-eluting stent implantation: insights and results from the PLATINUM diversity and PROMUS element plus post-approval study pooled analysis [published online October 18, 2017]. JAMA Cardiol. doi:10.1001/jamacardio.2017.3802